Sub-Navigation

• Investor News
• Ad-hoc Publications
• Archive
  • Overview
  • Investor News 2008
  • Investor News 2007
  • Investor News 2006
  • Investor News 2005
  • Investor News 2004
  • Investor News 2003
  • Investor News 2002
  • Investor News 2001
  • Investor News 2000
  • Ad-hoc 2008
  • Ad-hoc 2007
  • Ad-hoc 2006
  • Ad-hoc 2005
  • Ad-hoc 2004
  • Ad-hoc 2003
  • Ad-hoc 2002
  • Ad-hoc 2001
  • Ad-hoc 2000
  • Ad-hoc 1999
  • Ad-hoc 1998

Bayer Links

• Bayer Global
• Nachhaltigkeit
• Presse

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Archive
• Investor News 2008

Search

Here you find Investor News of year 2008. Ad-hoc messages issued in year 2008 can be found here.
Publications of the previous years are offered in the Archive Overview.

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Tuesday December 16, 2008

Milestone in the expansion of Bayer's global trait activities:

Bayer CropScience launches herbicide-tolerance technology for soybeans in the United States

Market launch in 2009

Monday December 08, 2008

Venous Blood Clot Prevention after Knee or Hip Replacement Surgery:

Xarelto® Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program

Pooled Analysis of RECORD1-4 Trials Confirms Significant Benefit in Clinical Outcomes for Patients Treated with Xarelto / RECORD4 Study Demonstrates Xarelto is the Only Oral Anticoagulant to Show Clinical Benefit in Head-to-Head Comparison Against U.S.-Approved Regimen of Enoxaparin

Tuesday November 25, 2008

Bayer Healthcare llc Reaches Settlement with U.S. Department of Justice on Investigation into former Diabetes Care Marketing Programs

Corporate Integrity Agreement to cover Bayer HealthCare Diabetes Care, Bayer HealthCare Pharmaceuticals, Medrad (including Possis), Intendis and Viterion TeleHealthcare

Friday November 14, 2008

Bayer MaterialScience lifts force majeure in the USA for most products

Monday November 10, 2008

Secondary Prevention in Acute Coronary Syndrome (ACS):

Bayer's Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome

Phase II Data Presented as Late-Breaker at American Heart Association Meeting / Phase III Study to be Initiated in December 2008

Wednesday October 29, 2008

Interim report for the third quarter of 2008:

Bayer optimistic about future business trend

Sales rise by 2.0 percent to EUR 7,948 million (Q3 2007: EUR 7,793 million) / HealthCare and CropScience improve earning power / MaterialScience earnings significantly lower / Group EBITDA before special items down 4.2 percent to EUR 1,493 million (Q3 2007: EUR 1,559 million) / Group EBIT before special items down 6.5 percent to EUR 891 million (Q3 2007: EUR 953 million) / Full-year guidance for 2008 confirmed / Continued earnings growth predicted for 2009

Thursday October 16, 2008

First estradiol-based oral contraceptive Qlaira® cleared for market launch in Europe

A new oral contraceptive providing the same estrogen produced by the female body

Monday October 06, 2008

Novel approach for the treatment of pulmonary hypertension

Bayer Reports Progress in Clinical Program for Riociguat

Positive Phase II Findings Reported at European Respiratory Society Meeting / Phase III Studies to Begin in 2008

Wednesday October 01, 2008

Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:

Bayer's Novel Anticoagulant Xarelto® now also Approved in the EU

Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care

Sunday September 28, 2008

Final Phase 2 Results Presented at Retina Society Meeting

VEGF Trap-Eye: New Data Confirm Successes in the Treatment of Age-related Macular Degeneration

Statistically significant reduction in the size of the affected area of the retina demonstrated

Thursday September 25, 2008

Bayer Schering Pharma AG

Squeeze-out entered in the Commercial Register

Squeeze-out of minority stockholders takes effect / Cash compensation of EUR 98.98 per share will be paid

Friday September 19, 2008

Bayer MaterialScience LLC declares force majeure in the USA

Tuesday September 16, 2008

Bayer HealthCare acquires German DIREVO Biotech AG

A recognized leader in protein engineering / Expanding technological know-how in biologicals / Strengthening Bayer HealthCare's commitment to develop innovative biologicals

Tuesday September 16, 2008

Venous Blood Clot Prevention after Elective Total Knee and Hip Replacement Surgery:

Bayer's Xarelto® Approved in Canada

First approval for Bayer's new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral, direct Factor Xa inhibitor in the world today

Monday September 08, 2008

New low-dose oral contraceptive YAZ® launched in Europe

24/4 dosing regimen has shown to reduce hormone fluctuations

Thursday September 04, 2008

Setting the course after a very successful first half of 2008:

Bayer CropScience plans investment of EUR 3.4 billion in research and development through 2012

Expansion of R&D program will strengthen basis for future growth / Achievement of target EBITDA margin of around 25 percent already expected in 2008 / Sales target of EUR 2 billion with new active ingredients now envisaged for 2009 / Launch of 10 new crop protection compounds with a peak sales potential of more than EUR 1 billion planned through 2012

Tuesday September 02, 2008

Bayer Submits Recombinant Human Thrombin for European Approval

Recothrom® would be the first recombinant human thrombin for use as a topical aid to surgical hemostasis in Europe

Sunday August 31, 2008

Secondary prevention in acute coronary syndrome (ACS):

Rivaroxaban Phase II Data in ACS to be Presented at AHA Congress in November 2008

First data presentation from large dose-finding trial involving about 3,500 patients / Acceleration of clinical development in acute coronary syndrome planned

Wednesday August 27, 2008

New Bayer CropScience active ingredient approved in Romania:

Thiencarbazone-methyl registered in first market

Annual sales potential of more than EUR 100 million for new corn herbicide

Thursday August 21, 2008

Bayer and Onyx continue clinical investigation of sorafenib:

New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer

Enrollment initiated in international phase III study

Thursday August 21, 2008

Further expansion of activities in China:

Bayer MaterialScience starts construction of a world-scale TDI plant in Shanghai

Annual capacity of 250,000 metric tons approved / Capacity can be increased to 300,000 metric tons per year / Start-up planned for 2010

Tuesday August 19, 2008

Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration

Study patients, on average, received only two additional doses following a 12-week fixed dosing period

Thursday August 07, 2008

Bayer Schering Pharma strengthens its oncology R&D portfolio

Bayer acquires Preclinical Anti-cancer Program from Nycomed

Company assuming full development and commercialization rights

Tuesday August 05, 2008

Bayer MaterialScience raises price for MDI

Wednesday July 30, 2008

Interim report for the second quarter of 2008

Bayer continues its success

Sales up 3.6 percent to EUR 8,511 million / EBITDA before special items increases by 5.0 percent to EUR 1,896 million / EBIT before special items improves by 5.3 percent to EUR 1,248 million / Full-year guidance for CropScience raised again / Group earnings forecast confirmed

Wednesday July 30, 2008

Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:

Bayer's Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.

Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues attributable to rivaroxaban after long-term exposure

Monday July 28, 2008

Another milestone for cancer drug from Bayer and Onyx:

Nexavar Approved for Treatment of Liver Cancer in China

Nexavar is First Approved Systemic Therapy to Treat the Disease

Friday July 25, 2008

Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:

Bayer's Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU

Final approval from the European Commission expected within the next few months

Friday July 25, 2008

Andreas Fibig named new Chairman of the Board of Management of Bayer Schering Pharma

Dr. Bernd Metzner to become new Board member of Bayer's pharmaceuticals subsidiary / Arthur Higgins and Werner Baumann to refocus on their leadership roles in the Bayer HealthCare subgroup following the successful integration of Bayer Schering Pharma

Friday July 25, 2008

Bayer welcomes the proposed EMEA labeling changes for moxifloxacin which are consistent with existing guidelines for appropriate use of fluoroquinolone antibiotics

Tuesday July 08, 2008

Innovative active ingredient provides reliable weed protection for corn:

Tembotrione from Bayer CropScience approved in Brazil

Launch of Soberan® planned for 2008

Tuesday July 08, 2008

First organ-specific diagnostic agent approved in the U.S. in more than a decade:

Primovist® approved in the U.S. for the Detection and Characterization of Liver Lesions

Thursday July 03, 2008

Bayer CropScience strengthens global position in insecticides market:

Insecticide Movento® approved in United States and Canada

Launch of Movento® planned for 2008

Wednesday July 02, 2008

Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology

Significantly Strengthens Consumer Care Division's Business in High Growth Chinese OTC Market

Wednesday July 02, 2008

Bayer Expands Hemophilia Portfolio

Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen

Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen's novel biotechnology research platform

Monday June 30, 2008

Venous Blood Clot Prevention after Knee and Hip Replacement Surgery:

Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death

Rivaroxaban shows superior efficacy to enoxaparin for this clinical outcome with a comparable safety profile / Pre-specified analysis of pooled data from RECORD 1-3 studies involving nearly 10,000 patients

Wednesday June 25, 2008

Suspensions lifted for insecticidal seed treatment products for use in oilseed rape

Tuesday June 24, 2008

Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United States

Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer's Women's Healthcare Business Unit expected

Friday June 20, 2008

Bayer MaterialScience raises prices for polycarbonates

Tuesday June 03, 2008

Bayer HealthCare successfully completes acquisition of Sagmel, Inc.'s OTC Business

Bayer Consumer Care's Presence in Eastern Europe Significantly Strengthened

Monday June 02, 2008

New Nexavar® Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology (ASCO) Annual Meeting

Friday May 30, 2008

Prevention of Thromboembolism after Knee Replacement Surgery:

Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial

Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice-Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates / RECORD4 Confirms Results of RECORD1, 2 and 3 / U.S. Submission Planned for mid 2008 / Prof. Turpie: "Rivaroxaban has the potential to revolutionize the way we prevent the formation of dangerous blood clots"

Monday May 19, 2008

Amikacin Inhale shows promising results in Phase II Study

Bayer together with Nektar Therapeutics present preliminary Phase II data for the adjunctive treatment of pneumonia in intubated and mechanically-ventilated patients

Monday May 19, 2008

Reformulated Liquid Leukine® Now Available in the U.S.

EDTA removed from liquid formulation / Restoration of U.S. supplies of Leukine

Friday May 16, 2008

Bayer and Onyx Announce Nexavar® Data Presentations at 44th American Society of Clinical Oncology (ASCO) Annual Meeting

Friday May 16, 2008

Phase III Asia-Pacific Study:

Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent

Trial Results Confirm Efficacy for Population Most Affected by the Disease

Thursday May 08, 2008

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration

International study to evaluate efficacy and safety in treating a leading cause of blindness

Tuesday May 06, 2008

Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe

Monday April 28, 2008

Bayer HealthCare and Regeneron Announce Encouraging 32-week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration

Gains in visual acuity achieved in initial 12-week fixed dosing phase of study maintained in PRN (as-needed) dosing phase

Friday April 25, 2008

Werner Wenning at the Bayer AG Annual Stockholders' Meeting

"2007 was Bayer's most successful year to date"

Previous year's record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded

Thursday April 24, 2008

Interim report for the first quarter of 2008

Bayer off to an excellent start in 2008

Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for CropScience raised / Positive Group forecast confirmed

Monday April 21, 2008

Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®

Wednesday April 02, 2008

Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical

Merger to Be Completed Shortly

Monday March 31, 2008

Bayer appeals invalidity ruling on its Yasmin® Patent

Appeal will be heard by the Federal Circuit

Wednesday March 26, 2008

Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period

Subsequent Offering Period Expires on Tuesday, April 1, 2008

Tuesday March 11, 2008

Bayer HealthCare to acquire OTC Business of Sagmel, Inc.

Acquisition strengthens Bayer Consumer Care's Presence in Eastern Europe

Monday March 03, 2008

Court decides against Bayer's Yasmin® patent

Bayer HealthCare margin target (EBITDA before special items) for 2008 slightly adjusted - margin target for 2009 remains unchanged / Company will consider its legal options

Thursday February 28, 2008

Spring Financial News Conference:

Wenning: 2007 was Bayer's most successful year to date

Sales grew 11.8 percent to EUR 32,385 million / EBITDA before special items advanced 21.4 percent to EUR 6,777 million / Performance target for 2007 exceeded: underlying EBITDA margin of 20.9 percent / EBIT before special items climbed 23.2 percent to EUR 4,287 million / Group net income totaled EUR 4,711 million - boosted by divestiture proceeds / Further earnings increase expected for 2008

Tuesday February 26, 2008

Bayer proposes increased dividend for 2007 of EUR 1.35 per share

Wednesday February 20, 2008

Bayer will vigorously defend itself against Kogenate patent infringement suit filed by Novartis

Monday February 18, 2008

Bayer and Onyx Provide Update on Phase III Trial of Nexavar® in Patients with Non-Small Cell Lung Cancer

Monday February 11, 2008

Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement

Monday January 28, 2008

Nexavar® Approved for the Treatment of Kidney Cancer in Japan

First approved oral targeted therapy for metastatic RCC in Japan

Thursday January 24, 2008

Bayer extends product portfolio for liver cancer patients in Japan

Japanese authorities grant priority review status for Nexavar® in liver cancer / Launch of liver-specific contrast agent Primovist® in Japan

Wednesday January 23, 2008

Bayer establishes US special access program for Leukine® while replacing current liquid formulation

Leukine lyophilized formulation temporarily reserved for patients with Acute Myelogenous Leukemia (AML) and those experiencing bone marrow transplantation graft failure or engraftment delay / Bayer will replace current 500 mcg liquid formulation; aims to restore US supplies of Leukine to current levels as quickly as possible

Thursday January 17, 2008

US Food and Drug Administration Approves RECOTHROM

Wednesday January 09, 2008

A new high-potential biofuel crop

Archer Daniels Midland Company, Bayer CropScience and Daimler to cooperate in Jatropha biodiesel project

Thursday January 03, 2008

B-cell chronic lymphocytic leukemia (B-CLL):

Expanded Labeling for MabCampath® in Europe